Skip to content

Biomarker Establishment for Superior Treatment of PTSD

Biomarker Establishment for Superior Treatment of PTSD

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03343028
Enrollment
292
Registered
2017-11-17
Start date
2016-09-30
Completion date
2019-09-30
Last updated
2020-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PTSD

Keywords

veterans, post traumatic stress disorder, depression

Brief summary

The purpose of Biomarker Establishment for Superior Treatment of PTSD is to accelerate research on the discovery of biological, neurological and neuroimaging markers for Post- Traumatic Stress Disorder (PTSD). The investigators hope to validate and extend the network efficiency and verbal memory biomarker for PTSD. The investigators hope to learn whether there are pretreatment biological factors that can predict response to therapy. They want to do this by understanding the brain network function, relating EEG to functional magnetic resonance imaging, and application of network analysis tool.

Interventions

OTHERPsychotherapy

Sponsors

New Mexico VA Healthcare System
CollaboratorFED
Stanford University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PTSD by VA clinicians and acceptance into PE or CPT treatment as part of the PCT * Veterans of any era

Exclusion criteria

* MRI safety contraindications * Active, uncontrolled medical illness * Acute suicidality * Current substance dependence * Current use of thyroid medication or active hyper/hypothyroidism * Neurological disorder affecting the CNS Seg stroke, epilepsy, tumorW or penetrating head injury * Use of PRN within 48 hours of the MRI/EEG

Design outcomes

Primary

MeasureTime frameDescription
Understanding the brain network function-neuroimaging and behavioral with Clinician-Administered PTSD Scale for DSM-5Approximately 3 monthsWe will be using CAPS 5

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026